Introduction: Almost every one in four women experiences an incomplete abortion in her life. During the twentieth century, uterine contents were evacuated using either forceps or curettage. Re-evaluation of this treatment seems logical. This study was designed to evaluate the results of medical treatment of first trimester incomplete abortion with methyl ergonovine maleate. Methods and Materials: An observational, descriptive-analytical and cross-sectional study was designed to assess the effectiveness of a maximum of four doses of 0.2mg methyl ergonovine maleate in the treatment of first trimester miscarriage. Patients received serum oxytocin concurrently. A total of 100 women were selected using convenience, consecutive sampling method. If after 24h, the interface line was seen completely and there was no bleeding, patients were discharged without medications. If not, they received oral methergine for 6days, qid.Results were analyzed by SPSS 11.5 software, chi-square and T-tests. Results: A total of 100 women aged between 14 and 45 years were selected. On the whole, methergine was successful in 97% of patients (injection or orally). Only 13% of the patients had mild side effects. Conclusion: Methergine is an effective and safe drug for the management of first trimester miscarriage.

Keywords: Incomplete abortion, miscarriage, methyl ergonovine maleate (Methergine)

Full-Text [PDF 114 kb]   (12865 Downloads)